Updates

ST-001 nanoFenretinide T-cell lymphoma clinical trial will be initiated at Rush University Medical Center (RUMC); IRB application currently being processed/reviewed at RUMC for targeting Phase I patient treatments in July 2020. SciTech discussing participation of additional clinical sites. For ST...

Read More
Learn more

SciTech Development's patented lead drug ST-001 nanoFenretinide strategic & clinical development plan in place for clinical trial study in T-cell non-Hodgkin's lymphoma (NHL) treatment. For ST-001 nanoFenretinide investment and partnering opportunities contact Lou Scarmoutzos | (617) 283-2182 | l...

Read More
Learn more

SciTech Development's optimized and expedited clinical trials plan potentially leading to ST-001 nanoFenretinide new drug approval in 2-3 years. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-263-4887 | eth@scitechdevelopment.com

Learn more

SciTech Development Lead Drug ST-001 nanoFenretinide: Strong Intellectual Property (IP), patent expiration February 6, 2030; Orphan Drug Designated; FDA Accepted IND. For ST-001 nanoFenretinide investment and partnering opportunities contact Earle Holsapple | +1-313-263-4887 | eth@scitechdevelopm...

Read More
Learn more

Breaking News: The U.S. Food and Drug Administration (FDA) has accepted SciTech Development’s Investigational New Drug (IND) Application for ST-001 nanoFenretinide treatment of T-cell non-Hodgkin's lymphoma (NHL). For ST-001 nanoFenretinide investment and partnering opportunities contact Earle H...

Read More
Learn more

SciTech Development poster presented at the Annual American Society of Hematology Meeting (ASH 2019) in Orlando, Florida. Poster title: "A Phase 1a/1b Trial of ST-001, a Fenretinide Phospholipid Suspension for 4-Hour Intravenous Infusion in Relapsed/Refractory T-Cell Non-Hodgkin's Lymphoma". An a...

Read More
Learn more

SciTech Development is seeking funding & strategic partnerships to conduct clinical trials to reconfirm the safety & efficacy of fenretinide in its new patented ST-001 nanoFenretinide formulation. For investment and partnering opportunities contact Lou Scarmoutzos | (617) 283-2182 | lou@scitechde...

Read More
Learn more

Earle Holsapple, SciTech President, will be presenting SciTech’s patented ST-001 nanoFenretinide technology at Biotech Showcase in San Francisco, CA on Monday, January 13, 2020 at 11:15 AM (PST) in Room Franciscan B at the Hilton San Francisco Union Square Hotel, 333 O’Farrell Street. For ST-001 ...

Read More
Learn more

Lead drug ST-001 nanoFenretinide

A clinical stage, biopharmaceutical company that has developed a proprietary nanoparticle drug delivery system (SciTech Drug Delivery Vehicle - SDV) that enables intravenous (IV) delivery of water-insoluble (or hydrophobic) drugs. Fenretinide, SciTech's lead API (active pharmaceutical ingredient), has been shown in numerous clinical trials to be a safe and effective anticancer therapy with targeted cancer destroying activity; however, its poor bioavailability (water insolubility) has impeded its development as a drug.  The patented combination of SciTech's new SDV and the fenretinide API has led to the company's lead drug candidate ST-001 nanoFenretinide with enhanced bioavailability (water solubilized) for the treatment of non-Hodgkin’s T-cell lymphoma (NHL). SciTech is actively seeking funding and strategic partnerships to conduct a Phase 1A & 1B clinical trial to reconfirm the safety and efficacy of fenretinide in its new nanoFenretinide formulation while also confirming a newly identified immune MOA (mechanism of action) as a further goal of the protocol.  

The FDA has recently accepted SciTech’s Investigational New Drug (IND) Application for ST-001 nanoFenretinide treatment of NHL. The FDA has designated ST-001 nanoFenretinide Orphan Drug Status. For investment and partnering opportunities contact Earle Holsapple | (313) 263-4887 | eth@scitechdevelopment.com 

Contact Us

Contact

Call now
  • (313) 938-5517

Address

Get directions
281 Kercheval Avenue
Grosse Pointe Farms, MI 48236
United States

Business Hours

Mon:7:00 AM – 9:00 PM
Tue:7:00 AM – 9:00 PM
Wed:7:00 AM – 9:00 PM
Thu:7:00 AM – 9:00 PM
Fri:7:00 AM – 9:00 PM
Sat:7:00 AM – 9:00 PM
Sun:7:00 AM – 9:00 PM
Contact Us
Message sent. We'll get back to you soon.